-
From the Editor-in-Chief
Measuring a Cancer Drug’s EffectivenessSurrogate endpoints can speed up drug approvals, but are they valid measures of effectiveness?
by William G. Nelson, MD, PhD
-
Forward Look
Cancer Treatments and Antioxidant Supplements Can Be a Bad MixChristine Ambrosone on what her research shows.
by Sue Rochman
-
Robotic Surgery and Cancer
Using robotic assistants for cancer surgery has become commonplace. Whether cancer patients benefit when a surgeon uses a robot remains unclear.
by Sue Rochman
-
Treating Cancer Patients With COVID-19: A New York City Experience
An analysis of cancer patients who were infected with the coronavirus and treated at Memorial Sloan Kettering Cancer Center in New York City suggests certain risk factors may predict more severe COVID-19.
by Anna Azvolinsky
-
What is a Super Responder?
Researchers are investigating why certain patients have an exceptional response to a particular drug.
by Bradley Jones
-
COVID-19 Exposes Health Inequities
At a symposium held during a virtual meeting of cancer researchers, panelists discussed the disproportionate impact COVID-19 has had on Black and Latino Americans, as well as members of other minority groups.
by Kevin McLaughlin
-
Pediatric Oncologists Underestimate Needs of Minority Parents
Research describes how communication gaps can shift extra burden to parents who are members of ethnic and racial minority groups.
by Marci A. Landsmann
-
Pushing Progress Forward
NCI Director Norman E. “Ned” Sharpless addresses disparities and maps out plans for the future amid “profound upheaval.”
by Kevin McLaughlin
-
Cancer and Older Adults: Can Oncologists Do Better?
Geriatric assessment reduces toxicity from treatment and improves quality of life in older adults with cancer.
by Marci A. Landsmann
-
Why Skip a Dose?
A survey of over 1,000 breast cancer patients prescribed endocrine therapy sheds light on low adherence.
by Emma Yasinski
Cancer Talk
Injection Immunotherapies Get FDA Approval
Giving immunotherapy drugs as injections, rather than intravenously, means patients can spend less time in the hospital or treatment center.
by Laura Gesualdi-Gilmore
Designing Clinical Trials for the PatientChallenges in developing and studying treatments call for new ways of thinking about cancer research.
by Eric Fitzsimmons
Treating Smoldering Multiple MyelomaA monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.
by Sandra Gordon
Immunotherapy Improves Survival in Bladder CancerNew research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore